Report library

MedTech analysis
Special bundles
Strategy analysis
Strategy analysis
Disease analysis
Company analysis
Drug analysis
MedTech analysis

Text search

Sort by Random

Display 15 Products per page

Post-AASLD US KOL Interview

$599.00

Over 95% SVR for easy-to-treat patients, and it’s one pill a day for 8-12 weeks for most. In that context, the only way you can improve up on that is to improve care for all populations, not just for easy-to-treat but the difficult-to-treat: decompensated cirrhotics, the post-transplant, and HIV co-infected patients.
December 16, 2014
Find out more
Stribild
Read More
Stribild (elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate [TDF]; Gilead/Japan Tobacco) is a single-tablet regimen for the treatment of HIV-1 infection. It is a co-formulation of marketed fixed-dose combination (FDC) Truvada, Vitekta, and Tybost.
June 28, 2019
Find out more
Alzheimer’s Disease KOL Interview – UK

$599.00

This interview with a UK key opinion leader (KOL) provides an overview of cost-effectiveness criteria that may be required to bring Alzheimer’s disease products successfully to the clinic in the UK. We also discuss current and potential treatment options, as well as unmet needs in Alzheimer’s disease.
January 20, 2019
Find out more
Disease Analysis: Hepatocellular Carcinoma (HCC)
Read More
Liver cancers can be differentiated based on the cell types they affect. The most common form of liver cancer is hepatocellular carcinoma (HCC), which accounts for 80–90% of liver cancer cases. HCC affects hepatocellular cells, or hepatocytes, which are the most abundant cell type in the liver and are responsible for the liver’s primary functions, such as bile production, protein synthesis, and detoxification. This differentiates HCC from other types of liver cancer such as cholangiocarcinoma, which affects the epithelial cells lining the bile ducts, and angiosarcoma, which affects the endothelial cells lining blood vessels of the liver.
May 19, 2022
Find out more
Point of Care Diagnostics

$4,750.00

Point of care in vitro diagnostics is being applied to an increasingly wide range of applications in infectious disease, cardiovascular, respiratory, and metabolic disease diagnosis and screening. The market is undergoing rapid expansion, primarily due to the demand for COVID-19 testing; however, other product segments will also contribute to market growth during the forecast period.
June 28, 2021
Find out more
Big Pharma Diversification Strategies

$2,995.00

Pressures ranging from continually declining revenues as a result of generics and impending biosimilars launches, to slow R&D productivity and market access restrictions could cause the Big Pharma peer set to evaluate business opportunities beyond pharmaceuticals.
March 4, 2018
Find out more
Flublok
Read More
Flublok (Sanofi) is a quadrivalent recombinant seasonal influenza vaccine that contains antigens from two A strains and two B strains specified by the World Health Organization seasonally for influenza vaccination.
January 10, 2019
Find out more
U.S. Ophthalmic Surgical Systems Market, April 2014

$3,750.00

This report discusses common ophthalmic diseases/disorders, prevalence, estimated U.S. procedure volumes, leading energy-based (laser and phacoemulsification, or “phaco”) ophthalmic surgical systems and their features, and novel technologies. A detailed U.S. market analysis, competitive analysis, and company profiles of selected U.S. competitors are also provided.
April 1, 2014
Find out more
Epilepsy KOL Interview – US, West

$599.00

A US key opinion leader (KOL) discusses the epilepsy treatment landscape, including new market entrant Epidiolex, and provides their perspective on late-phase pipeline anti-epileptic drugs such as Fintepla.
February 18, 2019
Find out more
MenABCW-135Y
Read More
GlaxoSmithKline’s MenABCW-135Y is a pentavalent meningococcal conjugate vaccine for the A, B, C, W-135, and Y meningococcal strains. With all of the vaccine’s announced Phase II trials now complete, Datamonitor Healthcare expects that Phase III trials could start by the end of 2019, and forecasts US and EU approvals in adolescents and adults to occur as early as 2022.
September 3, 2019
Find out more
Transcatheter Heart Valve Repair and Replacement Devices

$4,750.00

In 2020, the global market for transcatheter heart valve management products, including transcatheter aortic valve replacement (TAVR) and transcatheter mitral valve (TMV) repair products, totaled nearly $4.7bn, with TAVR products accounting for nearly 90% of sales.
August 30, 2021
Find out more
Acute Myeloid Leukemia (AML) KOL Interview – Italy

$599.00

An interview with an Italian key opinion leader (KOL) in which they provide insights into current prescribing habits, key marketed brands and their placement in the treatment algorithm, and expectations for late-phase pipeline therapies for AML. Key assets highlighted include Venclexta, Onureg, Idhifa, Tibsovo, magrolimab, crenolanib, gilteritinib, and Iomab-B.
March 14, 2022
Find out more
MenQuadfi
Read More
Sanofi’s MenQuadfi (quadrivalent polysaccharide tetanus toxoid conjugate vaccine) is a second-generation active polyvalent conjugate vaccine against group A, C, Y, and W meningococcal infection. It is presented as a sterile solution for injection containing Neisseria meningitidis capsular polysaccharide antigens individually conjugated to tetanus toxoid protein.
September 3, 2019
Find out more
Ninlaro
Read More
Ninlaro (ixazomib; Takeda) reversibly inhibits the 20S proteasome, resulting in the accumulation of proteins and eventually leading to the activation of apoptotic pathways.
August 9, 2018
Find out more
Alzheimer’s KOL Interview

$399.00

KOL is optimistic on amyloid-targeted therapy and believes IV therapy will be tolerated if approved.
October 21, 2015
Find out more

Sign up to the Pharma Intelligence Report Store Newsletter to get the latest blogs, news, reports and discounts!

Pharma Intelligence

This is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Call Back

Name

Email *

Company name *

Phone number *